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Abstract
Background: Acquired imatinib (IM) resistance is frequently characterized by Bcr-Abl mutations that affect IM
binding and kinase inhibition in patients with chronic myelogenous leukemia (CML). Bcr-Abl-T315I mutation is the
predominant mechanism of the acquired resistance to IM. Therefore, it is urgent to search for additional approaches
and targeting strategies to overcome IM resistance. We recently reported that nickel pyrithione (NiPT) potently inhibits
the ubiquitin proteasome system via targeting the 19S proteasome-associated deubiquitinases (UCHL5 and USP14),
without effecting on the 20S proteasome. In this present study, we investigated the effect of NiPT, a novel proteasomal
deubiquitinase inhibitor, on cell survival or apoptosis in CML cells bearing Bcr-Abl-T315I or wild-type Bcr-Abl.
Methods: Cell viability was examined by MTS assay and trypan blue exclusion staining assay in KBM5, KBM5R, K562,
BaF3-p210-WT, BaF3-p210-T315I cells, and CML patients’ bone marrow samples treated with NiPT. Cell apoptosis in
CML cells was detected with Annexin V-FITC/PI and rhodamine-123 staining followed by fluorescence microscopy and
flow cytometry and with western blot analyses for apoptosis-associated proteins. Expression levels of Bcr-Abl in CML
cells were analyzed by using western blotting and real-time PCR. The 20S proteasome peptidase activity was measured
using specific fluorogenic substrate. Active-site-directed labeling of proteasomal DUBs, as well as the phosphorylation
of USP14 was used for evaluating the inhibition of the DUBs activity by NiPT. Mouse xenograft models of KBM5 and
KBM5R cells were analyzed, and Bcr-Abl-related proteins and protein biomarkers related to proliferation, differentiation,
and adhesion in tumor tissues were detected by western blots and/or immunohistological analyses.
Results: NiPT induced apoptosis in CML cells and inhibited the growth of IM-resistant Bcr-Abl-T315I xenografts in nude
mice. Mechanistically, NiPT induced decreases in Bcr-Abl proteins, which were associated with downregulation of
Bcr-Abl transcription and with the cleavage of Bcr-Abl protein by activated caspases. NiPT-induced ubiquitin
proteasome system inhibition induced caspase activation in both IM-resistant and IM-sensitive CML cells, and the
caspase activation was required for NiPT-induced Bcr-Abl downregulation and apoptotic cell death.
Conclusions: These findings support that NiPT can overcome IM resistance through both Bcr-Abl-dependent and
Bcr-Abl-independent mechanisms, providing potentially a new option for CML treatment.
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Background
The constitutive activation of the Bcr-Abl tyrosine kin-
ase resulting from the t(9;22) chromosomal translocation
is necessary for the transformed phenotype of chronic
myelogenous leukemia (CML) [1–3]. The Bcr-Abl fusion
oncoprotein constitutively activates mitogenic signaling
pathways such as MAPK/ERK cascade, PI3K/Akt/
mTOR, and STATs pathways [4–6]. The activation of
these pathways in Bcr-Abl-expressing cells results in in-
creased expression of several anti-apoptotic proteins
(such as Bcl-2, Mcl-1 and XIAP), thereby conferring cell
survival advantage [7–9]. Thus, these abnormalities
should be targeted when designing novel strategies for
the treatment of CML. Imatinib (IM; Gleevec) was de-
veloped to selectively inhibit the abnormal tyrosine kin-
ase activity of Bcr-Abl and showed significant efficacy in
treatment for CML for inducing cytogenetic and mo-
lecular remission [10–12]. However, despite its impres-
sive efficacy, for a portion of patients, IM single-agent
therapy is not sufficient to control this disease. Some pa-
tients may respond suboptimally, and others fail to re-
spond at all [13, 14]. Among the mechanisms proposed
so far to account for the IM resistance, amplification
and mutation of Bcr-Abl are believed to be the predom-
inant ones. T315I mutation, the most stubborn point
mutation, accounts for about 20% of mutations within
the Abl kinase domain [15–17]. To overcome this resist-
ance, second-generation Abl kinase inhibitors such as
nilotinib, dasatinib, and bosutinib have been developed
and are effective against a range of Bcr-Abl mutations
except T315I [18–20]. Ponatinib, a third-generation TKI,
was specifically designed to inhibit BCR-ABL-positive
CML cells containing the T315I mutation. Although the
initial response to ponatinib is promising in CML patients
with single mutations in BCR-ABL, the response in ad-
vanced patients is limited because successive use of TKIs
leads to the evolution of compounded BCR-ABL kinase
domain mutations that show resistance even to ponatinib
[21]. Hence, additional strategies to overcome the IM re-
sistance are warranted.
Studies suggest that in addition to post-translational
modifications (mainly phosphorylation), abnormalities in
Bcr-Abl protein translation and degradation also play
critical roles in initiation, development, and induction of
drug resistance in CML [10]. Recent data suggest that
inhibiting the expression of Bcr-Abl may be a promising
strategy [22]. We and others have reported that metal-
containing compounds can induce cytotoxicity in cancer
cells via targeting the ubiquitin proteasome system
(UPS) [23–25]. Pyrithione (PT) possesses well-defined
metal-chelating properties, and the zinc complex of pyr-
ithione (ZnPT) was found to exert significant anti-
cancer effects [26]. And only recently we have definitely
confirmed that nickel pyrithione (NiPT) inhibits the 19S
proteasome-associated deubiquitinases (DUBs) USP14
and UCHL5, but not the 20S proteasome peptidases, and
the inhibition of proteasome-associated DUBs induces
NiPT-mediated cytotoxicity, revealing a novel mechanism
for the anti-cancer effects of nickel-containing compounds
[27]. Although proteasome inhibitors such as bortezomib
(PS-341) and gambogic acid (GA) have been reported to
downregulate or inhibit Bcr-Abl expression and induce
cell apoptosis in CML cells [28, 29], the role of DUB in-
hibitors, especially inhibitors of the 19S proteasome-
associated DUBs, in Bcr-Abl hematopoietic malignancies
remains unknown.
Here, we investigated the anti-neoplastic effects of NiPT
on Bcr-Abl wild-type and Bcr-Abl-T315I mutant cell lines,
primary cells from CML patients, and mouse IM-resistant
xenograft models. The results demonstrate that NiPT can
efficiently overcome IM resistance through both Bcr-Abl-
dependent and Bcr-Abl-independent mechanisms.
Methods
Chemicals
NiPT was synthesized in our laboratory, and a 20-mM
stock solution in dimethyl sulfoxide (DMSO) was stored
at −20 °C. b-AP15, Suc-LLVY-AMC, and HA-ubiquitin-
vinyl sulfone (HA-Ub-VS) were obtained from Boston
Biochem (MA, USA). Annexin V, propidium iodide (PI),
and rhodamine-123 were purchased from Sigma-Aldrich
(St. Louis, MO, USA). Proteasome inhibitor bortezo-
mib (PS-341) and caspase inhibitor z-VAD-fmk were
obtained from BD Biosciences (San Jose, CA, USA).
Antibodies against c-Abl (C-19), Mcl-1 (S-19), ubiqui-
tin (P4D1), caspase-3, -8, -9, apoptosis-inducing factor
(AIF), Bcl-2, USP14, and UCHL5 were from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Antibody
against poly(ADP)-ribose polymerase (PARP; clone
4C10-5) was from BD Biosciences. Antibodies against
phospho-c-Abl at Y245, phospho-Erk1/2 (T202/Y204),
Erk1/2, phospho-CrkL at Y207, CrkL, phospho-Akt,
Akt, RNA polymerase II (pol II), phospho-RNA Pol II
at Ser2 and Ser5, cyclin-dependent kinase 7 (CDK7),
CDK9, IκB-α, p27, phospho-eIF2α, eIF2α, CHOP, HA,
and XIAP were from Cell Signaling Technology (Bev-
erly, MA, USA). Antibodies against phospho-STAT5A/
B (Y694/Y699; clone 8-5-2), STAT5, Ki67, CD11b/c,
and CXCR4 were from Upstate Technology; mouse
monoclonal antibody against actin was from Sigma-
Aldrich. Antibodies against phospho-USP14 (S241) was
from ABGENT. Enhanced chemiluminescence (ECL)
reagents were purchased from Amersham Biosciences
(Piscataway, NJ, USA).
Cell culture
The KBM5 cell line expressing the 210 kD BCR-ABL
protein and lacking normal c-ABL was derived from a
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female myeloid CML patient in blast crisis as described
previously [30]. KBM5-T315I (KBM5R) cell line, an
imatinib-resistant KBM5 subline, was derived from
KBM5 by exposing to increasing concentrations of ima-
tinib, leading to the selection of survival clone harboring
T315I mutation as previously described [31, 32]. KBM5
cells were cultured in Iscove’s modified Dulbecco’s
medium (Gibco-BRL, Gaithersburg, MD) supplemented
with 10% fetal bovine serum in 5% CO2 at 37 °C. KBM5-
T315I cells were routinely maintained in the same
medium in the presence of 1 μM imatinib. In the study
where KBM5-T315I cells were compared with the par-
ental KBM5 cells, imatinib was washed off and KBM5-
T315I cells were cultured in drug-free medium for
several days before the experiments. BaF3-Bcr/Ablp210-
wt cells and BaF3-Bcr/Abl-T315I cells (kindly provided
by Dr. BZ. Carter, University of Texas M. D. Anderson
Cancer Center, Houston, USA) were derived from the
murine BaF3 cells by transfection using vectors MSCV-
BCR/ABL-PAC and MSCV-BCR/ABL-T315I-PAC [31].
Cells were selected in 2 μg/mL puromycin to achieve
stable expression as described previously [31]. Upon re-
ceipt of KBM5, KBM5R, BaF3-Bcr/Abl-wt, and BaF3-
Bcr/Abl-T315I cell lines, cells were expanded and frozen;
cells were not passaged for more than 6 months after re-
suscitation. K562 cell line was obtained from the ATCC
and routinely authenticated by karyotyping, short tan-
dem repeat profiling, assessment of cell morphology,
and species verification by isoenzymology. BaF3-Bcr/
Abl-wt, BaF3-Bcr/Abl-T315I, and K562 cells were cul-
tured in RPMI 1640 medium with 10% fetal bovine
serum as described previously [30–33].
Bone marrow samples from CML patients were ob-
tained from the Department of Hematology, the First
Affiliated Hospital of Sun Yat-sen University. The use
of these materials is approved by the Institutions with
the permission of the patients. Totally, 12 patients with
CML were recruited in this preclinical study. Mono-
nuclear cells were isolated using Histopaque gradient
centrifugation (density 1.077; Pharmacia, Uppsala,
Sweden). Contaminating red cells were lysed in 0.8%
ammonium chloride solution for 10 min. After isola-
tion, cells were washed with phosphate-buffered saline
and suspended in fresh RPMI 1640 culture medium
with 15% fetal calf serum as described previously [30].
All drug treatments were not started until the cells
were precultured in fresh medium for 24 h.
Western blot analysis
Whole cell lysates were prepared in RIPA buffer [29]
(1× PBS, 1% NP-40, 0.5% sodium deoxycholate, 0.1%
SDS) and was supplemented with freshly added 10 mM
β-glycerophosphate, 1 mM sodium orthovanadate,
10 mM NaF, 1 mM phenylmethylsulfonyl fluoride, and
1× Roche Complete Mini Protease Inhibitor Cocktail
(Roche, Indianapolis, IN). To detect the level of cyto-
chrome C and AIF in the cytosol, the cytosolic fraction
was prepared with digitonin extraction buffer (10 mM
PIPES [pH 6.8], 0.015% [wt/vol] digitonin, 300 mM su-
crose, 100 mM NaCl, 3 mM MgCl2, 5 mM EDTA, and
1 mM PMSF) as described previously [29]. Western
blot analysis was performed as we previously described,
using specific primary antibodies as indicated and ap-
propriate horseradish peroxidase (HRP)-conjugated
secondary antibodies as indicated.
Cell viability assay
MTS assay (CellTiter 96 Aqueous One Solution reagent;
Promega, Shanghai, China) was performed to test cell
viability. Briefly, 2 × 105/ml cells in 100 μl were treated
with NiPT for 48 h. At 3–4 h before culture termination,
20 μl of MTS reagent was added to the wells. The absorb-
ance density was read on a 96-well plate reader (Varioskan
Flash 3001, Thermo, Waltham, MA, USA) at wavelength
490 nm. IC50 values were calculated as the concentration
of the drug required to obtain 50% of maximal inhibition
in cell viability.
Cell death assay
CML cells were treated with increasing concentrations
of NiPT for indicated time periods, and 0.4% trypan blue
was added to monitor temporal changes in the incidence
of cell death under the light microscope. Cell apoptosis
was determined by flow cytometry or recorded under an
inverted fluorescence microscope using Annexin V-
fluoroisothiocyanate (FITC)/PI double staining [29, 30].
Cells were incubated with indicated concentration of
NiPT, collected and washed with binding buffer (BD
Biosciences Pharmingen), then incubated in working
solution (100 μL binding buffer with 0.3 μL Annexin V-
FITC) for 15 min in dark. Cells were washed and resus-
pended with binding buffer. PI (Sigma-Aldrich) was
added just before flow cytometric analysis. At the indi-
cated time points, the PI/Annexin V positive cells in the
culture dish were imaged with an inverted fluorescence
microscope equipped with a digital camera (AxioObs-
ever Z1, Zeiss, Germany).
Measurement of mitochondrial membrane integrity
The mitochondrial membrane potential (ΔΨm) of NiPT-
treated and NiPT-untreated cells were determined by
rhodamine-123 (Sigma-Aldrich, St. Louis, MO) staining.
Cells were treated with NiPT for 24 h and stained with
1 μM of rhodamine-123 for 1 h at 37 °C. Following the
staining, the cells were washed with PBS twice, and then
harvested for either imaging with an inverted fluores-
cence microscope or flow cytometry analysis.
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Peptidase activity assay
Fluorogenic substrate Suc-LLVY-AMC was used to as-
sess chymotrypsin-like activity of the 20S proteasome.
To evaluate in vitro proteasome inhibition, leukemia
cells were lysed in ice-cold lysis buffer (25 mM Tris-
HCl) for 10 min. Equal amounts of protein from each
sample were then treated with NiPT or bortezomib for
30 min, and then incubated at 37 °C with 25 nM
fluorogenic substrate for 1–2 h. Fluorescence intensity
was measured using a spectrophotometer at excitation
of 350 nm and emission of 438 nm (Varioskan Flash
3001, Thermo).
DUB active-site-directed labeling assays
Crude cell lysates extracted from cultured CML cells
using the DUB assay buffer (25 mM Tris-HCl pH 7.4,
5 mM MgCl2, 20 mM NaCl) were incubated with HA-
UbVS for 30 min at 37 °C, followed by boiling in the re-
ducing sample buffer and fractionated via SDS-PAGE.
HA-UbVS-labeled DUBs were immunodetected using
anti-HA antibodies.
RNA isolation and reverse transcriptase real-time quanti-
tative polymerase chain reaction (RT2-PCR)
Total RNA was extracted from 1 × 107 cells by use of
Trizol reagent (Invitrogen). After quantification by spec-
trophotometry, the first-strand cDNA was synthesized
from 500 ng total RNA using the RNA PCR Kit (AMV)
Ver.3.0 (TaKaRa, Dalian, China) and random primers.
Then 50 ng of total cDNA was used for real-time PCR
with the SYBR Premix Ex TaqIIKit (TaKaRa). The PCR
was performed using the Applied Biosystems™ 7500
Real-Time PCR Systems. The relative gene expression
was analyzed by the Comparative Ct method using 18S
ribosomal RNA as the endogenous control. The primers
for real-time PCR are as follows: Bcr-Abl forward, 5′-
AAG CGC AAC AAG CCC ACT GTC TAT-3′; reverse,
5′-CTT CGT CTG AGA TAC TGG ATT CCT-3′. 18S
forward, 5′-AAA CGG CTA CCA CAT CCA AG-3′;
reverse, 5′-CCT CCA ATG GAT CCT CGT TA-3′.
Nude mouse xenograft model
Nude Balb/c mice were bred at the animal facility of
Guangzhou Medical University. The mice were housed in
a barrier facility with a 12-h light dark cycle, with food
and water available ad libitum. 3 × 107 of KBM5 or
KBM5R cells were inoculated subcutaneously on the
flanks of 5-week-old male nude mice. At 72 h after the in-
oculation, mice were treated with either vehicle (10%
DMSO, 30% polyethylene glycol, and 60% physiological
saline, i.p.) or NiPT (2.5 mg/kg of body weight, i.p.) every
other day for a total of 11 or 14 days. Tumors were mea-
sured every day with the use of calipers. Tumor volumes
were calculated by the following formula: a2 × b × 0.4,
where a is the smallest diameter and b is the diameter
perpendicular to a. The animals were then euthanized,
and tumor xenografts were immediately removed,
weighed, and frozen or fixed for biochemical or histo-
logical analyses, respectively. All animal studies were
conducted with the approval of the Guangzhou
Medical University Institutional Animal Care and Use
Committee.
Immunohistochemical staining
Formalin-fixed xenografts were processed, paraffin-
embedded, and sectioned with standard techniques.
Tumor xenograft sections (4 μm) were immunostained
for c-Abl, Ubs, p27, CD11b/c, CXCR4, and Ki67. Max-
VisionTM reagent was applied to each slide (Maixin-
Biol) according to the manufacturer’s instructions.
Color was developed with 0.05% diaminobenzidine and
0.03% H2O2 in 50 mmol/L Tris-HCl (pH 7.6), and the
slides were counterstained with hematoxylin. A nega-
tive control for every antibody was also included for
each xenograft specimen by substituting the primary
antibody with preimmune rabbit serum.
Statistical analysis
All experiments were performed at least thrice, and the
results were expressed as mean ± SD where applicable.
GraphPad Prism 4.0 software (GraphPad Software) was
used for statistical analysis. Student’s t test was used to
compare the differences between variables. P value of
<0.05 was considered statistically significant.
Results
NiPT decreases viability of both Bcr-Abl wild-type and
Bcr-Abl-T315I cells
Various CML cell lines, including IM-sensitive Bcr-Abl
wild-type cell lines KBM5, BaF3-p210-WT, and K562,
as well as IM-resistant Bcr-Abl-T315I cell lines KBM5R
and BaF3-p210-T315I, were treated with various con-
centrations of NiPT for 48 h. A marked dose-
dependent decrease in viability of all CML cell lines
was observed in response to treatment with NiPT
(Fig. 1a), with 50% inhibitory concentration (IC50)
values of 0.14, 0.17, 0.3, 0.16, and 0.98 μM in KBM5,
KBM5R, BaF3-p210-WT, BaF3-p210-T315I, and K562
cells, respectively.
The effect of NiPT on cell viability was further exam-
ined in CML cell lines by trypan blue exclusion staining
assay. All CML cells were exposed to NiPT followed by
trypan blue staining, a time- and dose-dependent inhib-
ition of cell viability were observed (Fig. 1b), reflecting
its anti-leukemia activity in CML cells.
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Fig. 1 (See legend on next page.)
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NiPT induces apoptosis in both Bcr-Abl-WT and
Bcr-Abl-T315I cells
We next assessed the ability of NiPT to induce cell
death in Bcr-Abl wild-type and T315I mutant cell lines.
KBM5, KBM5R, K562, BaF3-p210-WT, and BaF3-p210-
T315I cells were exposed to different doses of NiPT, a
time-dependent increasing proportion of cell death was
observed by recording the number of Annexin V/PI
positive cells under an inverted fluorescence microscope.
The 24-h time point images were shown in Fig. 1c.
Similar results were obtained by flow cytometry ana-
lysis (Fig. 1d), supporting that NiPT induced apop-
totic cell death.
NiPT-induced apoptosis is associated with caspase
activation and decreased expression of anti-apoptotic
proteins in CML cells
To understand the mechanism of action underlying
NiPT-induced CML cell death, both Bcr-Abl wild-type
and Bcr-Abl T315I cell lines were treated with various
concentrations of NiPT for different durations, followed
by measurement of apoptosis-associated proteins. NiPT
markedly increased the cleavage of PARP, a hallmark of
apoptosis. In accordance with these findings, our data
showed that NiPT activates caspase 3, caspase 8, and
caspase 9 in both dose- and time-dependent manner
(Fig. 2a).
It is a widely accepted concept that mitochondrion is
the regulating center of apoptosis. We next examined
whether NiPT affects the integrity of mitochondrial
membranes. Our result showed that the integrity of
mitochondrial membranes was decreased in all CML cell
lines after the treatment with NiPT (Fig. 2b, c). The re-
lease of cytochrome C and apoptosis induce factor (AIF)
from mitochondria to the cytoplasm has been recog-
nized as the early signs of apoptosis [34]. We therefore
determined whether NiPT triggers the mitochondrial
pathway. As displayed in Fig. 2d, cytochrome C and AIF
release elevated at earlier time points, indicating that
NiPT can activate the mitochondrial apoptosis pathway
in CML cells.
To further investigate the mechanism of NiPT-
induced apoptosis, the expression of other apoptosis-
related proteins was detected. Results showed that there
was a marked decline of anti-apoptotic proteins Mcl-1,
XIAP, Bcl-2, and survivin (Fig. 2e).
NiPT-induced proteasome inhibition is associated with
ER-stress and cell apoptosis in CML cells
It is well established that inhibition of DUBs or the pro-
teasome causes accumulation of ubiquitinated proteins
[35]. Like in other cancer cells, we previously reported
[27], we found that NiPT dose- and time-dependently
induced accumulation of ubiquitinated proteins (Ubs)
and proteasome substrate protein p27 in all CML cell
lines we detected before the emergence of PARP cleav-
age (Fig. 3a). Specifically, NiPT treatment did not alter
the proteasome peptidases in KBM5 and KBM5R cells
either (Fig. 3b). The proteasome inhibitor bortezomib
served as a positive control for chymotrypsin-like activ-
ity inhibition.
In accordance with our previous report that NiPT po-
tently inhibits the ubiquitin-proteasome system via tar-
geting the 19S proteasome-associated DUBs, NiPT
treatment was able to compete with HA-UbVS for bind-
ing USP14 of DUB lysate from KBM5R cells (Fig. 3c).
Furthermore, the phosphorylation of USP14 (S241) was
substantially reduced in NiPT-treated CML cells, also in-
dicative of suppression of the DUB activity of USP14 by
NiPT treatment (Fig. 3d) [36].
Accumulation of ubiquitylated proteins induces un-
folded protein response (UPR) and apoptosis [37]. Exam-
ination of the effect of NiPT on endoplasmic reticulum
(ER) stress response showed that treatment of both
KBM5 and KBM5R cells with NiPT activates PERK-
mediated ER stress signaling, evidenced by significant in-
duction of p-eIF2a (Fig. 3e).
Together, these results suggest that NiPT-mediated
proteasome inhibition plays an important role in NiPT-
induced ER stress response and caspase activation in
CML cells.
NiPT downregulates Bcr-Abl protein and inhibits its
downstream signaling
We also found that NiPT downregulated the total and
phosphorylation levels of Bcr-Abl protein in both Bcr-
Abl-WT and Bcr-Abl-T315I cells in a dose- and time-
dependent fashion (Fig. 4a, b). Further examination
(See figure on previous page.)
Fig. 1 NiPT inhibits cell viability in CML cell lines. a, b NiPT decreases the viability of both IM-sensitive and IM-resistant CML cell lines. KBM5,
KBM5R, K562, BaF3-p210-WT, and BaF3-p210-T315I cells were exposed to NiPT in various concentrations for 48 h, and then were subject to MTS
assay. Cell viability was also examined by trypan blue exclusion staining assay. All CML cells were exposed to NiPT followed by trypan blue
staining. Graphs represent data from three repeats. Mean ± SD (n = 3). *P < 0.05,**P < 0.01, ***P < 0.001, versus control group. c, d NiPT
triggers cell apoptosis in CML cells. Cells were treated with different doses of NiPT for 24 h, then propidium iodide (PI) and Annexin V-FITC
were added to the culture medium and cell apoptosis were observed by recording the Annexin V-FITC/PI positive cells under an inverted
fluorescence microscope (c) or detected by Annexin V-FITC/PI double staining with flow cytometry (d). Mean ± SD (n = 3). Representative
images were shown.*P < 0.05,**P < 0.01, ***P < 0.001, versus control group
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displayed that NiPT affected the expression of Bcr-Abl
downstream target proteins. The phosphorylation of
STAT5, Akt, and Crkl was also significantly decreased in
a dose- and time-dependent manner, occurring earlier
than the downregulation of their total forms. Interest-
ingly, NiPT treatment also stimulated ERK phosphoryl-
ation, which may have something to do with the
inhibition of the catalytic process of autophagy in
leukemia cells, similar to the function of bortezomib re-
ported previously [38].
Bcr-Abl downregulation results from diminished gene
expression and caspase-dependent cleavage
To address the mechanism underlying the NiPT-
mediated Bcr-Abl protein downregulation in CML cells,
we analyzed the expression of Bcr-Abl at the transcrip-
tional level. KBM5 and KBM5R cells were treated with
increasing concentrations of NiPT for 6 h. RT-PCR re-
vealed that the mRNA level of Bcr-Abl was decreased to
some extent in both cells (Fig. 4c). The degree of mRNA
reduction is apparently less than the reduction of the
corresponding protein levels but the downregulation of
mRNA by NiPT likely contributes to the decrease of the
Bcr-Abl proteins. To further address this issue, RNA
polymerase II (RNA pol II) was analyzed. As shown in
Fig. 4d, the phosphorylation of RNA pol II was dimin-
ished to a certain extent in both KBM5 and KBM5R
cells by NiPT treatment. Together, NiPT leads to inhib-
ition of RNA polymerase followed by downregulation of
Bcr-Abl mRNA and protein levels, regardless of the mu-
tation status of the Bcr-Abl gene.
We and others have reported that Bcr-Abl could be
cleaved by caspase activation [29, 30]. To gain insight
into the mechanism of NiPT-induced Bcr-Abl decline,
we studied its dependence on the caspase activation.
Specifically, we observed that pan-caspase inhibitor z-
VAD-fmk mostly recovered NiPT-mediated cell death,
decreases of Bcr-Abl as well as its downstream proteins
to a certain extent but not ubiquitinated protein accu-
mulation (Fig. 4e, f ). These results demonstrate that cas-
pase activation triggered by NiPT-induced proteasome
inhibition is required for the downregulation of Bcr-Abl
and its downstream events.
Ex vivo effect of NiPT on primary monocytes from
patients with CML
The above results clearly indicate that NiPT-mediated
proteasome inhibition and cytotoxicity is effective in
both IM-sensitive and IM-resistant CML cells. We
next evaluated the ex vivo anti-neoplastic effect of
NiPT on bone marrow mononuclear cells from 12 pa-
tients with CML (4 patients are IM resistant). As dis-
played in Fig. 5a, NiPT decreased the cell viability of
primary monocytes from CML patients with IC50 values
ranging from 0.58 to 0.82 μM, while for the peripheral
mononuclear cells from three healthy volunteers the
IC50 values were more than 3.0 μM as we reported
recently [27].
It was further found that NiPT treatment at doses
from 0.25 to 1.0 μM for 36 h resulted in significant
apoptosis in all the monocytes from the 12 CML pa-
tients as detected by Annexin V/PI double staining
(Fig. 5b). NiPT treatment also significantly induced the
accumulation of ubiquitinated proteins and proteasome
substrate protein IκB-α (Fig. 5c), reduced the levels of
pro-caspase-3 and pro-caspase-9, Mcl-1, and induced
PARP cleavage in the primary monocytes (Fig. 5c, d).
These results are consistent with the in vitro inhibitory
effect of NiPT on both Bcr-Abl-WT and Bcr-Abl-T315I
cell lines, suggesting the potential use of NiPT for treat-
ment of CML patients.
NiPT inhibits the growth of Bcr-Abl-WT and Bcr-Abl-T315I
mutant xenografts in nude mice
We next evaluated the effect of NiPT in vivo using a
nude mouse xenograft model. KBM5 and KMB5R cells
were inoculated subcutaneously in nude mice. A marked
reduction in tumor growth was noted in NiPT-treated
mice versus mice receiving vehicle alone (Fig. 6a, b)
while body weight remained relatively stable in each
group (data not shown). Protein levels of Bcr-Abl and its
downstream targets Akt and STAT5 were significantly
decreased in the NiPT-treated tumors (Fig. 6c, d) while
the phosphorylation of ERK was highly accumulated,
consistent with the in vitro effect of NiPT. The ubiquiti-
nated proteins and proteasome substrates p27 were
highly accumulated in NiPT-treated tumor tissues versus
(See figure on previous page.)
Fig. 2 NiPT-induced apoptosis is associated with caspase activation. a NiPT leads to caspase-dependent cell apoptosis. KBM5, KBM5R, K562, BaF3-
p210-WT, and BaF3-p210-T315I cells were exposed to NiPT at the indicated dose for the indicated duration; cell lysates were then analyzed with
western blots for PARP, caspase-3, cleaved-caspase-3, caspase-8, and caspase-9. b, c NiPT reduces mitochondrial membrane potential in CML cells.
Cells were treated with different doses of NiPT for 24 h, mitochondrial membrane potential was assessed by rhodamine-123 staining coupled with
either fluorescence microscope (b) or flow cytometry (c). Mean ± SD (n = 3).*P < 0.05,**P < 0.01, ***P < 0.001, versus control group. d NiPT induces
the release of cytochrome C and AIF in CML cells. KBM5 and KBM5R cells were treated with 0.5 μM NiPT for 1, 3, and 6 h, cytoplasmic proteins
were analyzed by immunoblotting with cytochrome C and AIF antibodies. e NiPT downregulates anti-apoptotic proteins in CML cells. KBM5 and
KBM5R cells were treated with the indicted doses of NiPT for the indicated duration; cell lysates were then immunoblotted to assess the changes
of Mcl-1, XIAP, Bcl-2, Bcl-xl, and survivin
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Fig. 3 NiPT inhibits proteasome function in CML cells. a NiPT accumulates proteasome substrate proteins in CML cells. Cells were treated with various
doses of NiPT for 6 h. The protein levels of PARP, ubiquitinated proteins (Ubs), and p27 were detected using western blots. Actin was used as a loading
control. b NiPT has no obvious effect on the 20S proteasome peptidase activities in KBM5 and KBM5R cells. Cell lysate was treated with NiPT, and then
the CT-like activity at different times was recorded using the fluorogenic Suc-LLVY-AMC substrate. Mean ± SD (n= 3). c Active-site-directed labeling of
proteasomal DUBs. Cells were treated with NiPT, and then the cell lysate-contained DUBs were labeled with HA-UbVS. Labeled HA was detected via
western blotting. b-AP15 (0.15 μM) was used as a positive control. d NiPT inhibits the phosphorylation of USP14. Cells were treated with the indicated dose
of NiPT for the indicated duration. p-USP14 and total USP14 were detected with western blot. e NiPT treatment induces ER-stress response. KBM5 and
KBM5R cells were treated with 0.75 μM NiPT for the indicated duration, then cell lysates were immunoblotted to assess the changes of p-eIF2α and CHOP
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the control-treated models (Fig. 6d), indicating that
NiPT inhibits proteasome function in both IM-sensitive
and IM-resistant xenografts. The protein biomarkers re-
lated to proliferation, differentiation, and adhesion, such
as Ki67, CD11b/c, and CXCR4 were also downregulated
by the NiPT treatment in both KBM5 and KBM5R
models (Fig. 6d). Together, these results demonstrate
that NiPT inhibits xenografted Bcr-Abl-WT and Bcr-
Abl-T315I harboring cells in vivo.
Discussion
The development of tyrosine kinase inhibitors (TKIs)
has led to extended lifespans for many patients with
CML. Resistance against TKIs represents a relevant clin-
ical problem in treatment of CML. On the basis of their
activity against the spectrum of Bcr-Abl mutations
which have shown to be the most prominent mechanism
of resistance to imatinib [13–15], new TKIs have been
classified as second generation (such as nilotinib, dasati-
nib, and bosutinib) or third generation (such as ponati-
nib) TKIs. Although the second-generation TKIs can
effectively inhibit the phosphorylation of most of the
mutated Bcr-Abl (e.g., E255K, M351T), they had a little
effect on Bcr-Abl-T315I [18–20]. The third-generation
TKIs ponatinib has activity against all of the known Bcr-
Abl mutations including T315I. However, the resistance
to ponatinib would limit the application of the agent to
a certain extent [21, 22]. In addition, Bcr-Abl-expressing
cells are relatively resistant to apoptosis induced by con-
ventional cytotoxic agents [39, 40]. These observations
suggest that additional approaches and targeting strat-
egies are needed to provide more treatment options for
CML patients. In light of the possibility to overcome
kinase inhibitor resistance, several compounds including
heat shock protein 90 (Hsp90) inhibitors, arsenic trioxide,
proteasome inhibitors. and others have been found to lead
to CML cell death through downregulation of Bcr-Abl ex-
pression or a loss of Bcr-Abl stability other than direct
kinase inhibition [41]. Taken together, Bcr-Abl downregu-
lation is the common effect and is likely the major factor
inducing apoptosis in Bcr-Abl-expressing cells. Additional
compounds that induce rapid changes in Bcr-Abl levels
with limited impact on other proteins are still needed.
Previously, we have reported that NiPT could produce
tumor tissue-specific proteasome-associated DUBs in-
hibition and tumor-specific toxicity, which might have
clinical significance for designing novel strategies for
cancer treatment [27]. In this study, we analyzed the
mechanism of action of NiPT, the nickel ion, and PT-
chelating product with previously reported inhibitory
activity of 19S proteasome-associated DUBs, in overcoming
IM-resistant CML cells in vitro, ex vivo and in vivo. In the
in vitro study, NiPT dose- and time-dependently decreased
cell viability and induced cell death in both IM-sensitive
and IM-resistant cell lines; in the mononuclear cancer cells
from either IM-sensitive or IM-resistant patients with CML,
NiPT also had the same effects as in cultured cell lines; in
the in vivo experiment, both IM-sensitive and IM-resistant
xenografted tumors were all sensitive to NiPT treatment.
These results have clearly demonstrated that NiPT can effi-
ciently induce cytotoxicity in IM-resistant cancer cells. To
our knowledge, this is the first report to show that NiPT, as
a novel inhibitor of 19S proteasome-associated DUBs, is
effective in vitro and in vivo against CML cells, including
those with the Bcr-Abl-T315I mutation.
UPS inhibitors have been reported to be effective in
overcoming IM-resistant cancer cells via either inhibit-
ing Bcr-Abl expression or interfering other mechanisms
[28, 29, 32], but the mechanism is far from being fully
understood. Recently, we have reported that NiPT is
able to inhibit the activity of 19S proteasome-associated
DUBs USP14 and UCHL5 but not the 20S proteasome
[27]. We confirmed that NiPT induces cell apoptosis
and overcomes IM-resistance in CML cells through both
Bcr-Abl-dependent and Bcr-Abl-independent mecha-
nisms. On the one hand, NiPT inhibits the transcription
of the Bcr-Abl gene, and future studies need to investi-
gate the possibility that NiPT activates caspases which
cleaves RNA pol II leading to decrease of Bcr-Abl
mRNA. On the other, NiPT-induced caspase activation
cleaves Bcr-Abl (Fig. 4c–f ), thus leading to Bcr-Abl
downregulation and cell proliferation inhibition. Here,
we proposed a novel pathway that NiPT-mediated UPS
(See figure on previous page.)
Fig. 4 NiPT treatment downregulates Bcr-Abl and its downstream signaling proteins. a, b NiPT decreases the protein levels of Bcr-Abl and its
downstream targets. CML cells were treated with NiPT as indicated, then harvested for western blot analyses for the indicated proteins. c NiPT
decreases mRNA expression of Bcr-Abl. KBM5 and KBM5R cells were exposed to 0.5 μM NiPT for 3 or 6 h. The steady state Bcr-Abl mRNA level
was measured using RT2-PCR, and its expression level relative to the control was calculated. Mean ± SD (n = 3). *P < 0.05,**P < 0.01, versus control
group. d NiPT inhibits cellular activity of RNA pol II. KBM5 and KBM5R cells were dose-dependently treated with NiPT, the phosphorylated and
total protein levels of RNA pol II, CDK7, and CDK9 were analyzed with western blot. e Proteasome inhibition mediated caspase activation induces
Bcr-Abl downregulation. KBM5 and KBM5R cells were treated with 0.5 μM NiPT for the indicated durations. The Ubs, cleaved-caspase-3, and
Bcr-Abl were analyzed with western blot. Representative images are shown. f NiPT decreases Bcr-Abl and the downstream signaling proteins in
a caspase-dependent manner. KBM5R cells were treated with 0.5 μM NiPT for 12 h in the absence or presence of 25 μM pan-caspase inhibitor
z-VAD-fmk. b-AP15 (150 nM) was used as a positive control of proteasomal DUB inhibition. The total and phosphorylated Bcr-Abl and its
downstream proteins, Ubs, PARP, caspase-3, and caspase-8 were analyzed using western blots. Representative images are shown
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Fig. 5 NiPT triggers cell apoptosis and proteasome inhibition in cancer cells from CML patients. a NiPT decreases cell viability of CML patient
cancer cells. CML cells from 12 CML patients were treated with NiPT at the indicated doses for 48 h, and cell viability was detected by the MTS
assay. Mean ± SD (n = 3). b NiPT induces cell apoptosis in CML patient cancer cells. Cancer cells from CML patients were isolated and incubated
with NiPT for 36 h, followed by detecting the Annexin V/PI positive cells by flow cytometry. Representative images are shown. c NiPT accumulates
ubiquitinated proteins and IκB-α in CML cancer cells. Cancer cells from three CML patients were treated with NiPT for 6 h. The indicated proteins were
analyzed using western blots. (#3, 5: imatinib-sensitive patients; #12: imatinib-resistant patient). d NiPT induces cleavage of PARP and caspase-3 or
caspase-9, and downregulates Mcl-1 protein in patients’ cancer cells. Cells from CML patients were treated with NiPT, and the indicated proteins were
detected with western blots (#5, 8: imatinib-sensitive patients; #11: imatinib-resistant patient)
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inhibition and caspase activation are responsible for the
downregulation of Bcr-Abl protein, which contributes to
overcoming IM-resistance by NiPT. Like in other cancer
cells, NiPT induced UPS inhibition in both Bcr-Abl
wild-type and T315I cell lines, as well as in primary
mononuclear cancer cells derived from CML patients in-
cluding IM-resistant or IM-sensitive in vitro. It was fur-
ther confirmed that NiPT also inhibited USP function in
the xenografted tumor model bearing wild-type- and
T315I-Bcr-Abl genes in vivo. We have reported that pro-
teasome inhibition induced ER-stress response plays an
important role in caspase activation and cell apoptosis
[42]. The induced ER-stress response accumulates Ca2+
in cytoplasm to alter mitochondrial membrane perme-
ability, leading to the release of cytochrome C and AIF,
followed by caspase activation and apoptosis. Here, we
also found that NiPT time-dependently induced the ER-
stress response pathway, while the release of cytochrome
C and AIF was induced and the anti-apoptotic proteins
like Bcl-2, XIAP, and Mcl-1 were dramatically decreased.
The released apoptotic factors bind with caspase-9 form-
ing a protein complex, inducing caspase activation
(Fig. 2). After caspase activation, on the one hand, it in-
duced PARP cleavage and apoptosis; on the other hand,
it directly cleaved Bcr-Abl protein which has been con-
firmed in our work (Fig. 4e, f ).
Bcr-Abl is a constitutively active tyrosine kinase that
phosphorylates several substrates, and activates multiple
signal transduction pathways such as MAPK/ERK, PI3K/
AKT, and STAT3/STAT5, all of which are responsible
for cell proliferation and survival [4–6]. The downstream
target of STAT5 responsible for enhanced survival of
Bcr-Abl cells are involved in the transcription of Mcl-1,
survivin, or Bcl-2 [7–9]. Treatment with NiPT resulted
in downregulation of Mcl-1, Bcl-2, and XIAP (Fig. 2e).
Even though NiPT may impact on multiple molecules,
in the case of Bcr-Abl, loss of signaling is associated with
the onset of CML cell apoptosis. Research suggests that
sustained activation of ERK inhibits the maturation step
of the autophagy process [38]. Interestingly, we have also
noted that NiPT, like bortezomib, triggers ERK phos-
phorylation distinctly, but this is not sufficient to fully
protect CML cells from DUB inhibition-mediated
apoptosis. NiPT treatment stimulated ERK phosphoryl-
ation may attribute to the inhibition of the catalytic
process of autophagy in leukemia cells, just like the
action of bortezomib reported previously [43]. In this re-
gard, the inhibition of autophagy by NiPT may enhance
the chemotherapy efficacy of this agent in CML cells.
Future studies need to be performed to investigate the
mechanism involved in autophagy inhibition by NiPT.
Taken together, both caspase-induced apoptosis and
Bcr-Abl downregulation likely contribute to the cyto-
toxic effects of NiPT on IM-sensitive or IM-resistant
cancer cells.
At present, most studies on Bcr-Abl inhibition are
centered in finding tyrosine kinase inhibitors that dir-
ectly inhibit tyrosine kinase activity. Here, we propose
an alternative strategy to enhance Bcr-Abl cleavage by
activating the caspase system. In summary, here, we
have demonstrated the mechanisms of overcoming IM-
resistance by NiPT both in the Bcr-Abl-T315I cells and
in the xenografted Bcr-Abl-T315I harboring cells. These
findings suggest for the first time that NiPT may have
clinical benefit for patients with CML, particularly in
those suffering from imatinib-resistance and the recur-
rent forms of this disease, providing great importance in
the future clinical CML therapy.
Notably, we previously reported the anti-tumor effects
of NiPT in other types of tumor models, such as lung can-
cer (A549), hepatocarcinoma (SMMC-7721), and mye-
loma (U266) [27]. We found that although higher doses
were needed for those cancers compared with CML cells,
NiPT could inhibit cell growth of all these cancer models,
which raises the possibility that NiPT could have wide ap-
plication for the treatment of different kinds of cancer in
the future.
Conclusions
NiPT induces Bcr-Abl decrease in Bcr-Abl wild-type and
Bcr-Abl-T315I mutation cells through downregulation of
Bcr-Abl transcription and Bcr-Abl protein cleavage medi-
ated by proteasome inhibition-induced caspase activation.
Meanwhile, 19S proteasome-associated DUB inhibition
plays an important role in NiPT-induced caspase ac-
tivation and apoptosis. We here propose an alternative
(See figure on previous page.)
Fig. 6 In vivo effect of NiPT on KBM5- and KBM5R cell-derived mouse xenograft models. Nude mice bearing wild type and T315I-mutant Bcr-Abl
xenograft tumors were treated with either vehicle or NiPT (2.5 mg/kg/day) for 11–14 days after inoculation of KBM5 and KBM5R cells. a NiPT
inhibits tumor growth in vivo. Tumor growth curves were recorded every day in two sets of experiments. Mean ± SD (n = 6). *P < 0.05, **P < 0.01,
***P < 0.001, versus NiPT-treated group. b On day 14 after inoculation, the mice were sacrificed, and the tumor tissues were weighed and imaged.
***P < 0.001, versus control group. c, d Western blot analyses (c) and/or immunohistochemistry staining for proteasome substrates (ubiquitinated
proteins, p27), Bcr-Abl-related proteins (Bcr-Abl, p-Bcr-Abl) and its downstream proteins (Stat5, p-Stat5, Akt, Erk, p-Erk), and protein biomarkers related
to proliferation (Ki-67), differentiation (CD11b/c), and adhesion and migration (CXCR4) in the xenograft tumor tissues from the KBM5 vehicle group
(#2, 5, 6), KBM5 NiPT-treated group (#27, 28, 29), KBM5-T315I vehicle group (#16, 18, 19), and KBM5R-T315I NiPT-treated group (#35, 36, 37). In panel d,
the proteins of interest are immunostained brown. All the immunohistochemical stainings were repeated in three mouse tumor tissues and the
representative images are shown
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strategy to overcome IM resistance by enhancing Bcr-Abl
downregulation, which should have great clinical signifi-
cance in IM-resistant cancer therapy.
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